influenza
viru
one
preval
ancient
infect
human
fifth
world
popul
infect
influenza
viru
annual
lead
high
morbid
mortal
particularli
infant
elderli
immunocompromis
us
alon
influenza
outbreak
lead
roughli
death
year
current
vaccin
antiinfluenza
drug
limit
use
due
high
mutat
rate
viru
side
effect
recent
year
rna
interfer
trigger
synthet
short
interf
rna
sirna
rapidli
evolv
potent
antivir
regimen
properli
design
sirna
shown
function
potent
inhibitor
influenza
viru
replic
sirna
outperform
tradit
small
molecul
antivir
number
area
eas
design
modest
cost
fast
turnaround
although
specif
tissu
deliveri
remain
major
bottleneck
clinic
applic
rnai
gener
intranas
applic
sirna
respiratori
virus
includ
limit
influenza
viru
experienc
signific
success
optim
review
influenza
viru
widespread
respiratori
pathogen
human
anim
major
caus
morbid
mortal
global
infect
acut
peak
roughli
third
day
exposur
last
week
larg
varieti
influenza
viral
strain
gener
combin
mutat
reassort
genom
segment
lead
antigen
shift
open
access
antigen
drift
turn
attempt
vaccin
antivir
design
neverend
battl
influenza
viru
strain
isol
diverg
speci
chicken
duck
hors
pig
mani
shown
cross
speci
boundari
small
mutat
chang
rais
specter
global
epidem
regular
influenza
season
diseas
suggest
persist
natur
reservoir
clearli
identifi
new
continu
emerg
viral
strain
recent
pandem
swineorigin
evok
imag
histor
spanish
flu
kill
million
peopl
infect
million
third
world
popul
time
although
small
molecul
antivir
regimen
avail
influenza
limit
efficaci
alreadi
render
useless
due
resist
viral
mutat
given
bleak
scenario
rna
interfer
rnai
offer
fresh
potenti
effect
antivir
strategi
mechan
antiinfluenza
rnai
trigger
use
synthet
small
interf
rna
sirna
promot
sequencespecif
degrad
silenc
target
viral
rna
articl
review
effort
antiinfluenza
sirna
area
analyz
futur
potenti
summar
challeng
lie
ahead
articl
issu
cover
variou
antivir
approach
influenza
viru
includ
tradit
current
one
offer
comprehens
perspect
battl
prehistor
pathogen
influenza
commonli
call
flu
highli
contagi
diseas
start
suddenli
common
symptom
includ
high
fever
headach
weak
cough
sore
throat
runni
stuffi
nose
bodi
ach
healthi
adult
influenza
selflimit
acut
diseas
last
day
howev
fatal
highrisk
group
includ
peopl
year
older
chronic
medic
condit
asthma
diabet
heart
diseas
weak
immun
aid
patient
pregnant
women
young
children
influenza
also
invit
opportunist
pathogen
lead
secondari
infect
bacteri
pneumonia
common
mode
horizont
spread
influenza
viru
person
person
via
respiratori
droplet
aerosol
produc
cough
sneez
infect
peopl
transmiss
influenza
viru
respiratori
virus
also
occur
touch
contamin
object
door
knob
follow
touch
nose
eye
influenza
virus
member
orthomyxovirida
famili
viral
genom
consist
eight
neg
sens
antimrna
sens
rna
segment
togeth
segment
code
distinct
viral
protein
three
subunit
viral
rnadepend
rna
polymeras
rdrp
pa
hemagglutinin
ha
neuraminidas
na
major
surfac
glycoprotein
nucleocapsid
protein
np
matrix
protein
nonstructur
protein
gene
product
indispens
optim
viru
replic
cell
cultur
anim
host
genom
viral
rna
vrna
wrap
np
protein
result
ribonucleoprotein
complex
specif
transcrib
viral
rdrp
produc
mrna
tail
serv
templat
viral
protein
synthesi
copi
vrna
also
produc
complementari
rna
crna
lack
tail
positivesens
lack
translat
crna
serv
templat
vrna
base
sequenc
divers
np
protein
influenza
virus
current
classifi
three
type
b
c
although
influenza
virus
caus
morbid
mortal
influenza
virus
caus
pandem
outbreak
swineorigin
influenza
viru
two
viral
protein
neuraminidas
na
ion
channel
protein
target
us
food
drug
administr
fda
approv
influenza
antivir
drug
oseltamivir
tamiflu
zanamivir
relenza
na
inhibitor
amantadin
symmetrel
rimantadin
inhibit
unfortun
widespread
viral
resist
drug
class
particularli
inhibitor
mutagenesi
import
caus
viral
resist
primarili
due
errorpron
copi
rna
genom
viral
rdrp
abil
viru
reassort
genom
segment
limit
number
viral
drug
target
influenza
viru
creat
concern
develop
new
influenza
therapi
rnai
recent
discov
regulatori
pathway
initi
doublestrand
rna
rnai
work
diceandslic
mechan
long
dsrna
first
cleav
special
rnase
name
dicer
gener
basepair
product
twonucleotid
long
dicer
product
commonli
known
short
interf
rna
sirna
antisens
strand
sirna
recruit
rnainduc
silenc
complex
risc
key
catalyt
compon
slicer
rnase
argonaut
use
antisens
rna
strand
guid
risc
engag
complementari
target
mrna
slice
destroy
lead
silenc
express
cognat
gene
howev
use
rnai
gene
silenc
tool
realli
prosper
demonstr
chemic
synthes
sirna
transfect
mammalian
cell
cultur
simul
natur
rnai
specif
destroy
complementari
target
mrna
first
proof
concept
synthet
sirna
antivir
also
appear
wherebi
growth
respiratori
syncyti
viru
rsv
inhibit
target
essenti
viral
mrna
code
viral
transcript
factor
p
phosphoprotein
viral
f
fusion
protein
case
specif
ablat
correspond
protein
mrna
demonstr
moreov
also
shown
mrna
rsv
vulner
sirna
viral
genom
contrast
resist
like
due
fact
neg
strand
rna
viral
genom
gener
wrap
viral
nucleocapsid
protein
n
np
henc
inaccess
guid
strand
rna
sinc
sirnabas
approach
appli
success
major
acut
viral
infect
includ
first
report
influenza
chen
laboratori
result
detail
due
small
genom
virtual
rna
viral
gene
serv
essenti
role
viru
replic
conceptu
silenc
inhibit
viru
growth
extent
born
larg
bodi
accumul
evid
varieti
virus
mention
high
mutabl
rna
viral
genom
gener
reassort
genom
segment
segment
virus
gener
mani
strain
subtyp
influenza
viru
influenza
viru
exampl
boast
ha
nine
na
subtyp
effect
strategi
sirna
design
gener
base
follow
consider
first
genom
rna
encapsid
n
np
protein
sirna
target
mrna
instead
genom
second
order
design
sirna
remain
effect
despit
sequenc
chang
time
conserv
sequenc
given
mrna
target
influenza
viru
batteri
sirna
specif
np
pa
ns
gene
design
test
variou
degre
inhibit
multipl
subtyp
exampl
mous
experi
antinp
antipa
sirna
inhibit
growth
follow
strain
subtyp
inhibit
rang
fold
apuerto
ahong
netherland
ahong
avian
contrast
possibl
design
broadspectrum
sirna
diverg
ha
na
sequenc
stretch
conserv
nucleotid
could
found
sequenc
also
underscor
reason
rapid
resist
current
drug
target
neuraminidas
list
publish
sirna
sequenc
target
influenza
viral
mrna
shown
tabl
obligatori
parasit
virus
depend
cellular
function
product
infect
influenza
viru
except
thu
altern
complementari
antivir
strategi
would
base
knock
cellular
function
inhibit
viru
growth
henc
associ
patholog
concept
recent
valid
small
molecul
inhibitor
exampl
chemic
inhibitor
cellular
signal
pathway
facilit
poxviru
replic
prevent
vaccinia
variola
viru
infect
anoth
exampl
target
cellular
receptor
block
viral
infect
earliest
stage
inde
small
molecul
bind
hiv
coreceptor
shown
promis
effect
hiv
antivir
recent
year
genomewid
highthroughput
sirna
screen
perform
first
surrog
drosophila
cell
cell
human
origin
identifi
cellular
gene
need
influenza
viru
growth
gene
set
discov
differ
group
show
substanti
common
mani
valid
secondari
knockdown
togeth
studi
reveal
essenti
role
dozen
cellular
gene
influenza
replic
notabl
one
includ
son
dna
bind
protein
son
cdclike
kinas
vacuolar
atpas
copi
coat
vesicl
transport
copg
fibroblast
growth
factor
receptor
fgfr
protein
glycogen
synthas
kinas
nuclear
import
compon
proteas
calciumcalmodulindepend
protein
kinas
cam
kinas
reliabl
approach
evidenc
part
rediscoveri
compon
previous
known
import
influenza
growth
nuclear
export
factor
valid
sirna
cellular
gene
purchas
multipl
commerci
sourc
could
expedit
develop
antiinfluenza
drug
anim
studi
follow
clinic
trial
cellular
gene
perform
import
function
normal
cell
potenti
sideeffect
drug
sirna
genuin
concern
howev
gene
product
may
partial
dispens
least
short
term
exampl
sirnabas
silenc
cellular
gene
reveal
actinregulatori
protein
vasp
vasodilatorstimul
phosphoprotein
zyxin
dispens
growth
cultur
cell
dispens
valid
fact
vasp
zyxin
knockout
mice
fulli
viabl
fertil
virtual
phenotyp
interestingli
protein
also
anoth
actinregulatori
protein
profilin
found
essenti
morphogenesi
respiratori
syncyti
viru
knockdown
vasp
zyxin
profilin
sirna
strongli
inhibit
progeni
viru
synthesi
togeth
result
provid
proofofconcept
viral
essenti
cellular
function
less
essenti
cell
thu
target
antivir
least
short
time
frame
acut
respiratori
infect
influenza
rule
antiinfluenza
potenc
synthet
sirna
first
test
cultur
cell
use
seri
sirna
concentr
madindarbi
canin
kidney
mdck
cell
line
commonli
use
routin
influenza
viru
growth
well
suit
purpos
mention
human
alveolar
epitheli
carcinoma
cell
line
also
use
human
relev
particularli
cellular
gene
knockdown
studi
use
human
genomespecif
sirna
cell
cultur
studi
live
viru
infect
substitut
transfect
influenzabas
report
plasmid
express
enzym
luciferas
amen
highthroughput
screen
test
smaller
scale
egg
yolk
sac
embryon
chicken
egg
also
use
liber
viru
allanto
fluid
harvest
assay
influenza
viru
titer
measur
routin
hemagglutin
plaqu
assay
less
commonli
use
immunofluoresc
imag
luciferas
assay
use
report
plasmid
luciferas
gene
transcrib
influenza
viral
promot
thu
requir
viru
infect
gener
result
differ
screen
platform
highli
corrobor
ie
sirna
strongli
inhibit
influenza
viru
product
cultur
cell
also
inhibit
viru
product
chicken
embryo
sirna
show
potenc
influenza
viru
cell
cultur
test
mous
model
one
earliest
report
black
mice
use
synthet
sirna
complex
cation
polym
polyethyleneimin
pei
administ
intraven
iv
anoth
studi
sirna
complex
oligofectamin
invitrogen
administ
appli
intranas
signific
reduct
influenza
titer
anim
lung
well
relief
symptom
observ
case
sirna
targetspecif
activ
interferon
effect
prophylaxi
therapi
moreov
influenzaspecif
sirna
treatment
broadli
effect
protect
anim
lethal
challeng
highli
pathogen
avian
influenza
virus
subtyp
rout
particularli
promis
prevent
therapi
influenza
respiratori
viral
infect
sinc
deliv
sirna
directli
lung
primari
site
infect
thu
ensur
specif
deliveri
minim
system
sirna
loss
toxic
see
sirnabas
antivir
approach
follow
advantag
tradit
antivir
compound
highli
potent
antivir
agent
prevent
well
therapeut
valu
ii
design
synthes
hour
new
one
rapidli
deploy
resist
first
set
encount
iii
appli
combin
sirna
multidrug
regimen
reduc
odd
resist
target
multipl
coinfect
virus
iv
use
noninvas
readili
administ
via
standard
handheld
inhal
v
dri
sirna
powder
form
rel
stabl
transport
without
refriger
remot
locat
extrem
climat
need
influenza
patient
add
water
mix
use
nasal
drop
inhal
aerosol
togeth
intranas
antiinfluenza
sirna
match
viru
speed
tissu
specif
broadspectrum
potenc
therapeut
regimen
howev
intranas
applic
need
optim
potenti
side
effect
previous
mention
zanamivir
sold
name
relenza
glaxosmithklin
appli
via
handheld
nasal
inhal
gener
welltoler
howev
sideeffect
may
includ
exasper
asthma
bronchospasm
cough
dizzi
headach
nausea
sinu
inflamm
sore
throat
stuffi
nose
facial
swell
although
exact
mechan
reaction
remain
unclear
path
pharmaceut
develop
antiinfluenza
sirna
share
gener
hurdl
confront
sirna
first
report
sirna
may
trigger
innat
immun
reaction
tolllik
receptor
tlr
pathway
lead
inflamm
shock
howev
appear
extent
nonspecif
reaction
vari
among
cell
type
sirna
sequenc
transfect
reagent
other
shown
optim
paramet
inde
lead
safe
effect
sirna
exampl
motif
identifi
immunostimulatori
henc
avoid
design
sirna
sequenc
hand
pei
almost
invari
kill
mice
administ
wherea
reagent
includ
oligofectamin
transitko
miru
pose
problem
second
stabil
sirna
biolog
fluid
remain
concern
although
applic
rsv
sar
coronaviru
parainfluenza
influenza
appear
larg
bypass
problem
address
concern
variou
chemic
modif
sirna
substitut
ribos
ring
test
retain
specif
potenc
without
caus
untoward
reaction
addit
novel
second
gener
transfect
reagent
nanoparticl
technolog
develop
bypass
tlr
pathway
shown
promis
result
interest
novel
modal
immunostimul
sirna
may
actual
har
broadspectrum
antivir
effect
recent
studi
nonpair
uridin
bulg
passeng
strand
complementari
guid
strand
introduc
sirna
semliki
forest
viru
sfv
modifi
sirna
resembl
microrna
mirna
famili
short
rna
natur
found
normal
cell
sequenc
modif
reduc
silenc
activ
sirna
increas
proinflammatori
cytokin
product
result
enhanc
protect
sfv
anoth
studi
residu
part
mrna
follow
sirnamedi
cleavag
shown
translat
shorter
ntermin
protein
fragment
cleavag
direct
downstream
cytotox
tcell
epitop
shorter
fragment
contain
epitop
gener
protect
immun
respons
recent
approach
easili
test
adopt
influenza
viral
target
summari
signific
optim
antiinfluenza
sirna
drug
may
clinic
trial
short
order
